3 mEq/L [SD, 4.5] to 136.5 mEq/L [SD, 4.4], P = 0.0002), while the serum sodium concentration was significantly decreased from baseline in the placebo group (135.7 mEq/L [SD, 4.1]

to 135.0 mEq/L [SD, 4.3], P = 0.0060) (Table 2). Tolvaptan significantly improved ascites-related clinical symptoms, bloated feeling (P = 0.0090), malaise (P = 0.0074), sensation AZD3965 in vitro of pressure in the decubitus position (P = 0.0017) and breathing difficulty (P = 0.0233) compared with placebo (Table 3). Forty-eight patients showed adverse events in the placebo group (60.0%) and 60 in the tolvaptan group (73.2%). Adverse events observed in the tolvaptan group during the trial period at 3% or greater frequency were thirst, constipation, renal impairment, diarrhea,

pollakiuria, pyrexia, hepatic encephalopathy, vomiting, insomnia, stomatitis Opaganib manufacturer and pruritus (Table 4). Ten patients showed serious adverse events in the placebo group (12.5%) and seven in the tolvaptan group (8.5%). Serious adverse events observed in the tolvaptan group were disseminated intravascular coagulation, liver cirrhosis, portal vein thrombosis, omphalitis, bile duct cancer, liver malignant neoplasm, hepatic encephalopathy, renal impairment, respiratory failure and hemoperitoneum (Table 5). No marked abnormalities were clinically observed in clinical laboratory tests, vital signs and 12-lead electrocardiograms. IN LIVER CIRRHOSIS patients with ascites, reduction in bodyweight from baseline was significantly greater in the tolvaptan group than in the placebo group. Reductions in abdominal circumference (parameter for assessing ascites retention) and ascites volume were greater in the tolvaptan group than in the placebo group. In addition, improvement rates of ascites-related clinical

symptoms and lower limb edema (a symptom associated with hepatic edema) were higher in the tolvaptan group than in the placebo group. Decrease in bodyweight is considered to reflect improvement of ascites and lower limb edema.[15] In this trial, ascites was considered to be improved by tolvaptan, because abdominal circumference and ascites volume both decreased, and ascites-related clinical symptoms improved. As worsening of ascites, lower limb edema and ascites-related clinical symptoms results in deterioration of QOL in patients with hepatic MCE公司 edema,[3] tolvaptan may also improve QOL. Liver cirrhosis patients are reported to have low serum sodium concentration.[16] In this trial, mean serum sodium concentration in patients was also around the lower limit of the normal range at the start of treatment. Kim et al. reported that, in liver cirrhosis patients registered on the waiting list for liver transplantation, the hazard ratio of death increased 1.05-fold (95% CI, 1.03 to 1.08) per 1 mEq/L decrease in serum sodium concentration when serum sodium concentration was between 125 and 140 mEq/L.[17] In this trial, mean serum sodium concentration increased in the tolvaptan group and decreased in the placebo group.